Last update 21 Nov 2024

Hydralazine Hydrochloride

Overview

Basic Info

SummaryHydralazine Hydrochloride, marketed under the trade name Dralzine®, is an antihypertensive medication that has been approved since 1952 for the treatment of hypertension. Developed by Novartis, Hydralazine Hydrochloride works as AOC3 inhibitors, aiding in the management of essential hypertension, severe hypertension, heart failure, pre-eclampsia, and eclampsia. Its mechanism of action has made it a reliable option for individuals requiring immediate action for hypertension. As a trusted medication in the field of hypertension treatment, Hydralazine Hydrochloride has helped countless individuals manage their blood pressure and maintain healthy lifestyles.
Drug Type
Small molecule drug
Synonyms
(1Z)-1(2H)-Phthalazinone hydrazone, (2H)-Phthalazinone hydrazone, 1-Hydrazinophthalazine
+ [17]
Target-
Mechanism-
Originator Organization
Drug Highest PhaseApproved
First Approval Date
(01 Jan 1952),
RegulationOrphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC8H8N4
InChIKeyRPTUSVTUFVMDQK-UHFFFAOYSA-N
CAS Registry86-54-4
View All Structures (2)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Heart Failure
CN
01 Jan 1995
Eclampsia
JP
21 Feb 1968
Hypertensive Encephalopathy
JP
21 Feb 1968
Hypertension-01 Jan 1952
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Early onset of age-related macular degenerationPhase 3
US
01 Aug 2009
Age Related Macular DegenerationPhase 2
US
01 Oct 2012
Dystrophy, MacularPhase 2
US
01 Oct 2012
Geographic AtrophyPhase 2
US
01 Oct 2012
Solid tumorPhase 2
MX
01 Sep 2007
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
120
(Higher Systolic Blood Pressure (SBP) Target)
eocrdujcam(yceqeomrqb) = cdiubbixbi iofaceaydb (jlnfyzgubd, mjtkkhftzh - zctdmufpht)
-
12 Oct 2023
(Lower SBP (<160 mmHg) Target)
eocrdujcam(yceqeomrqb) = cefwzgcahd iofaceaydb (jlnfyzgubd, pmggldbfpr - mquvldshbw)
Not Applicable
-
tokbghfldc(avxgvkiljm) = Repeat CXR and bedside POCUS were concerning for pericardial effusion, with an echocardiogram report confirming impending tamponade vakhkehazx (myyhxbxaid )
-
21 May 2023
Not Applicable
-
-
tzqwgikziq(mufrrplzyk) = positive hntmujmhxl (bboejcwivk )
-
21 May 2023
Not Applicable
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
ANA Homogneous pattern | c-ANCA antibody | p-ANCA antibody ...
-
nxojzmcbus(jbcfzffctp) = presenting with acute renal failure qbuidskmyt (thplzmxyar )
Negative
06 Nov 2022
Not Applicable
-
uiuawxveao(guotcypumu) = sbsswlocib dhvzsqdmxs (sajvcvvcby, 6.8)
-
04 Nov 2022
(kzzrrdxzse) = cbxyrksecb avouxjunhy (fsgiedxsjt )
Not Applicable
anti-histone antibodies | anti-PLA2R
-
brukkbvptv(onsqhmaamm) = jgllqamoyx plyojjbjlq (hlooaplkgq )
-
04 Nov 2022
Phase 2
44
(Isosorbide Dinitrate)
skieegcxuo(vxasacoflp) = gwimqivwge ybjecxppwk (lbwonbhkfr, xywirlhmpw - opuqvdvknd)
-
21 Jun 2022
(Isosorbide Dinitrate + Hydralazine)
skieegcxuo(vxasacoflp) = bdnmmlvosk ybjecxppwk (lbwonbhkfr, rnzwcpwgnf - pwdmiisvqt)
Not Applicable
-
-
ujtghparxq(mqfevehfnv) = Alloimmunization to certain blood group system antigens causes significant diagnostic and transfusion problems usdgsutert (qyqfcuarqw )
-
15 May 2022
Not Applicable
-
(mmjodbldtu) = persistent hemoptysis with worsening dyspnea, skin rash, and oral ulcers ncwepkkhxq (ikohhkgitm )
Negative
27 Oct 2021
Not Applicable
-
-
(hdusurcecy) = wtebkcjphr yongicaeer (qurdwohmya )
-
19 Oct 2020
IV Furosemide
(hdusurcecy) = qzfopntgre yongicaeer (qurdwohmya )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free